Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13728346 | 0.88 | HCAR3 (0.44) | DEGS1RAB9ASMN1; SMN2MLYCDHCAR3 | |
| SCHEMBL15508497 | 0.84 | PTK2 (0.56) | PTK2CYP1A2GAARAB9AHCAR3 | |
| SCHEMBL13838444 | 0.82 | GRIN2B (0.44) | DEGS1MLYCDHCAR3NNMT | |
| SCHEMBL27211369 | 0.82 | ALDH1A1 (0.44) | DEGS1SMN1; SMN2MLYCDHCAR3MAPT | |
| SCHEMBL30473730 | 0.82 | ALDH1A1 (0.44) | DEGS1SMN1; SMN2MLYCDHCAR3MAPT | |
| SCHEMBL1854705 | 0.80 | MAPK1 (0.59) | PTK2CYP1A2GAADEGS1RAB9A | |
| SCHEMBL7922969 | 0.79 | MEN1 (0.48) | CYP1A2GAADEGS1RAB9ANPC1 | |
| SCHEMBL27596021 | 0.78 | PIK3C3 (0.49) | PIK3C3 | |
| SCHEMBL7093993 | 0.77 | PTK2 (0.62) | PTK2CYP1A2GAARAB9ASMN1; SMN2 | |
| SCHEMBL6867485 | 0.77 | ADORA3 (0.43) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018086703-A1 | DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9512116-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512116-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512116-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-09-03 | — | — | US | disclosed |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-09-03 | — | — | US | disclosed |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-09-03 | — | — | US | disclosed |
| WO-2014059333-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014059333-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | PTK2 1528/4885CYP1A2 4570/4885GAA 994/4885 |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | PTK2 1528/4885CYP1A2 4570/4885GAA 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.